ResistanceBio is a biotechnology startup founded in 2019 with the slogan "Harnessing evolution to overcome treatment-resistant cancer." The company operates in the Biotechnology and Health Care industries, with its headquarters based in the United States. The core focus of resistanceBio lies in aiding patients in their battle against treatment-resistant cancer. The company has developed a unique capability to discover and address clinical treatment resistance pre-clinically. Notably, it secured a Debt Financing investment on 29 January 2024, indicating investor confidence in its potential to drive innovation in cancer treatment.
No recent news or press coverage available for resistanceBio.